New drug cocktail aims to beat tough infection in HIV patients
NCT ID NCT07585461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding a fluoroquinolone antibiotic to the standard three-drug treatment helps HIV patients with a serious bacterial infection called disseminated MAC. About 124 adults will be randomly assigned to get either the standard therapy or the four-drug combo for the first 8 weeks. The main goal is to see if more patients feel better by day 28, with fewer fevers and improved symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluoroquinolone (levofloxacin or moxifloxacin) added to standard triple therapy
What this could lead to
If it works, this could lead to a more effective treatment for HIV patients with severe MAC infections, improving early recovery and reducing bacterial load.
What could go wrong
This is an early-stage trial with only 124 participants, so results may not apply to everyone. Adding a fluoroquinolone also raises risks like heart rhythm problems and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••